Answers are grounded in this paper and cite their sources.
This Viewpoint examines the appropriateness of FDA accelerated approval of novel gene therapies to treat boys with Duchenne muscular dystrophy following clinical trials with surrogate outcomes that did not demonstrate net benefits.
No takes yet. Share an insight, caveat, or question.
David M. Rind (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: